Joincare Pharmaceutical Group Industry (600380.SH): The approval for listing of Lize microspheres for injection of aliprazole microspheres.

Joincare Pharmaceutical Group Industry (600380.SH) announced that its holding subsidiary, Livzon Pharmaceutical Group Inc., received approval from the National Medical Products Administration for the issuance of a "Drug Registration Certificate" (Certificate Number: 2025S01188) for the injection of Aripiprazole microspheres. The injection of Aripiprazole microspheres, developed by Livzon Microsphere, is a long-acting sustained-release formulation for the treatment of adult schizophrenia. It was submitted for market application in September 2023 with acceptance number: CXHS2300080. The monthly dosing of Aripiprazole microspheres can improve medication compliance, help reduce relapse and hospitalization rates, and alleviate the economic and social burden on patients. As of the date of this announcement, only Livzon Microsphere has obtained a production license for Aripiprazole long-acting microsphere formulations, and there are no other Aripiprazole microsphere products on the market globally. According to IQVIA estimate data, the terminal sales of antipsychotic drugs in China in 2024 are approximately RMB 60.48 billion, with long-acting formulation products accounting for around RMB 14.18 billion.